Department of Thoracic Surgery;
J Thorac Dis. 2012 Feb;4(1):40-7. doi: 10.3978/j.issn.2072-1439.2011.05.02.
To elucidate the differences in chemosensitivity to anticancer drugs between primary and metastatic lesions in non-small cell lung cancer (NSCLC) patients, we examined the in vitro chemosensitivities of surgically resected NSCLC tissues.
A total of 32 specimens were enrolled: 26 specimens of primary lesions paired with metastases in the lymph node, 3 specimens of primary lesions paired with metastases in the adrenal gland, and 3 specimens of primary lesions paired with metastases in the lung. The collagen gel droplet embedded culture drug test (CD-DST) was applied to examine the sensitivity of the tissues to anticancer drugs, including cisplatin, gemcitabine, vinorelbine, docetaxel and 5-fluorouracil.
The degree of in vitro sensitivity to each anticancer drug varied between the primary and metastatic lesions. The sensitivity of the paired metastatic lesions was significantly lower than that of the primary lesions only for gemcitabine (P=0.029), vinorelbine (P=0.012), and docetaxel (P=0.009). The incidence of cases diagnosed as CD-DST-sensitive among the paired metastatic lesions was significantly lower than that for the primary lesions for vinorelbine (P=0.035) or docetaxel (P=0.022). The difference in the sensitivity to gemcitabine between the primary and paired non-lymphatic metastases was clearer than that between the primary lesion and paired lymph node metastases.
The sensitivities of the paired metastatic lesions to some anticancer drugs were significantly lower than those of the primary lesions. When performing chemotherapy based on CD-DST data using primary tumors from patients with postoperative recurrence, an appropriate regimen can be selected by carefully considering these differences.
为了阐明非小细胞肺癌(NSCLC)患者原发灶和转移灶对抗癌药物敏感性的差异,我们检测了手术切除的 NSCLC 组织的体外化疗敏感性。
共纳入 32 例标本:26 例原发性病变与淋巴结转移灶配对,3 例原发性病变与肾上腺转移灶配对,3 例原发性病变与肺转移灶配对。采用胶原凝胶液滴嵌入培养药物试验(CD-DST)检测组织对包括顺铂、吉西他滨、长春瑞滨、多西他赛和 5-氟尿嘧啶在内的抗癌药物的敏感性。
每种抗癌药物在原发灶和转移灶之间的体外敏感性程度不同。仅在吉西他滨(P=0.029)、长春瑞滨(P=0.012)和多西他赛(P=0.009)方面,配对转移灶的敏感性明显低于原发灶。在配对转移灶中被诊断为 CD-DST 敏感的病例比例明显低于原发灶,尤其是对于长春瑞滨(P=0.035)或多西他赛(P=0.022)。与原发灶和淋巴结转移灶相比,原发灶和非淋巴结转移灶之间对吉西他滨的敏感性差异更明显。
配对转移灶对某些抗癌药物的敏感性明显低于原发灶。当根据术后复发患者的原发肿瘤的 CD-DST 数据进行化疗时,需要仔细考虑这些差异,选择合适的方案。